Company intelligence / Profile preview

SM Discovery Group

Durham, England, United Kingdomsmdiscovery.com ↗
Ownership
Private
Development stage
Other
01

Overview

SMDG is an award-winning preclinical-stage biotechnology company developing innovative therapeutic platforms to address neurodegenerative diseases and rare pediatric neurological disorders. Their research emphasizes precision targeting of the blood-brain barrier using engineered peptides for gene therapy and other advanced modalities. No clinical results have been published as of June 2025; the company remains in preclinical development.

Therapeutic areas
Neurology
Modalities
Gene therapySmall moleculePeptidesDrug delivery devices
Industry
Biotech
02

Drug pipeline

4 assets

SMDG-AD01

Preclinical

3 more assets in the full pipeline.

Beyond the preview

Go deeper on SM Discovery Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM Discovery Group.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call